Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on April 30, 2007, regarding an event that occurred on April 25, 2007. The filing addresses a change in the composition of the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance matters and does not contain financial performance data.
Material Changes
The material change reported is the resignation of Peter Barrett, Ph.D., from the Board of Directors. Dr. Barrett, a Partner at Atlas Venture and a founding member of the Board since the Company's inception in 2002, intends to resign effective at the 2007 Annual Meeting of Stockholders on June 1, 2007. He will not stand for reelection to focus on his private portfolio companies.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to noting that Dr. Barrett has been a valuable member of the Board.
Key Facts for Investor Verification
- Peter Barrett, Ph.D., is resigning from the Board of Directors.
- The resignation is effective at the Annual Meeting on June 1, 2007.
- Dr. Barrett was a founding Board member representing Atlas Venture since 2002.
- The stated reason for resignation is to focus on private portfolio companies.